StreetInsider.com News Articles

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

TEL AVIV, Israel, June 22, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury. The study is designed to generate efficacy data supporting the Company's preparations for a first in human clinical trial.

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

Mon, 22 Jun 2026 07:00:00 -0400

The study is being conducted in accordance with a development framework previously discussed with the U.S. Food and Drug Administration (FDA)

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

Wed, 17 Jun 2026 07:00:00 -0400

TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings.

The study evaluated key safety parameters including toxicology, tumorigenicity, and biodistribution in 248 animals monitored for up to 39 weeks following implantation. Results demonstrated no treatment related toxicity, no evidence of tumor formation, and no migration of the implant to distant organs or tissues, supporting

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

Wed, 17 Jun 2026 07:00:00 -0400

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

Wed, 17 Jun 2026 07:00:00 -0400

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

Wed, 17 Jun 2026 07:00:00 -0400

Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

Tue, 09 Jun 2026 07:00:00 -0400

TEL AVIV, Israel, June 9, 2026 /PRNewswire/ -- – Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, today announced the initiation of GMP manufacturing activities at Sheba Medical Center's Advanced Biotherapy Center, marking a significant milestone in the Company's transition toward clinical development.

The manufacturing activities are designed to validate Matricelf's clinical production process under GMP conditions and represent a key step in the Company's preparations for a first in human clinical trial of its personalized neural tissue implant for spinal cord injury patients.

The

Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

Tue, 09 Jun 2026 07:00:00 -0400

The

Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

Tue, 09 Jun 2026 07:00:00 -0400

The

Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

Tue, 09 Jun 2026 07:00:00 -0400

The

Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing

Mon, 30 Mar 2026 07:00:00 -0400

TEL AVIV, Israel and KYOTO, Japan, March 30, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, today announced it has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine.